Authors
Andrew J Vickers
Published in
Current opinion in urology. Nov 03, 2026. Epub Nov 03, 2026.
Abstract
National policy recommendations on prostate cancer early detection using prostate-specific antigen (PSA) have focused on determining whether the evidence in favor of screening is sufficiently strong to warrant population-based implementation. We review the literature using the alternative framework of decision-analytic evaluation of screening policy.
Randomized trial data are very clear: while PSA screening does reduce mortality, it remains open to question whether this benefit outweighs the well known harms resulting from overdiagnosis and overtreatment. But recent research on use of markers and MRI to reduce overdiagnosis and active surveillance to reduce overtreatment have transformed our ability to reduce the harms of prostate cancer. Almost all high-income countries have PSA policies based on shared decision-making. This sort of disorganized screening has led to the worse possible outcomes of high harm, low benefit and gross inequity. A modeling study has shown implementation of population-based screening would reduce both PSA testing and prostate cancer overdiagnosis.
High-income countries need to make the hard choice between a population-based screening program carefully designed to reduce the harms of PSA - that is, organized screening - or restrict PSA screening altogether.
PMID:
43023833
Bibliographic data and abstract were imported from PubMed on 13 Nov 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 14
- Comments 0